Shares in Flamel Technologies (NSDQ:FLML) rose today after the pharmaceutical company met expectations on Wall Street with its 3rd quarter results.
The Venissieux, France-based company posted a loss of -$22.3 million on sales of $32.1 million for the 3 months ended Sept. 30, for bottom-line growth of 20% despite a sales loss of 32% compared with the same period last year.
Adjusted to exclude 1-time items, losses per share were -8¢, ahead of consensus on The Street, where analysts were looking for sales of $30.7 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Flamel Technologies tops Q3 revenue, EPS estimate appeared first on MassDevice.